文献速递妇科肿瘤

曲妥珠单抗联合卡铂-紫杉醇治疗HER2过表达子宫浆液性癌的随机II期试验

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
PubMed 文献 · J Clin Oncol · 2018-03-27

这项多中心随机II期试验纳入61例晚期或复发HER2/neu过表达的子宫浆液性癌患者,比较卡铂-紫杉醇联合或不联合曲妥珠单抗的疗效。

要点

  • 曲妥珠单抗联合卡铂-紫杉醇可显著改善HER2阳性子宫浆液性癌的无进展生存期。
  • 联合治疗在初治III/IV期和复发患者中均显示PFS获益。
  • 毒性未增加,无意外安全信号,但总生存获益尚待进一步研究。

核心结论

  • 在HER2/neu过表达的晚期或复发子宫浆液性癌中,卡铂-紫杉醇联合曲妥珠单抗耐受良好并延长无进展生存期。

研究设计与样本

  • 多中心、随机II期试验,2011年8月至2017年3月随机分配61例患者,58例可评估。

主要发现

  • 毒性在两组间无差异,未出现意外安全信号。

关键数值与推荐

  • 入组条件:初治III期或IV期或复发HER2/neu阳性子宫浆液性癌。
  • 治疗方案:卡铂-紫杉醇6周期,试验组联合静脉曲妥珠单抗直至进展或不可耐受毒性。
  • 主要终点:无进展生存期,采用单侧log-rank检验比较组间差异。

临床怎么用

  • 对于HER2/neu过表达的晚期或复发子宫浆液性癌,可考虑在卡铂-紫杉醇基础上联合曲妥珠单抗。

局限性

  • II期试验样本量较小(61例随机),总生存数据尚未成熟,需进一步研究确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Uterine serous carcinoma is a rare, aggressive variant of endometrial cancer. Trastuzumab is a humanized monoclonal antibody that targets human epidermal growth factor receptor 2 (HER2)/neu, a receptor overexpressed in 30% of uterine serous carcinoma. This multicenter, randomized phase II trial compared carboplatin-paclitaxel with and without trastuzumab in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu. Methods Eligible patients had primary stage III or IV or recurrent HER2/neu-positive disease. Participants were randomly assigned to receive carboplatin-paclitaxel (control arm) for six cycles with or without intravenous trastuzumab (experimental arm) until progression or unacceptable toxicity. The primary end point was progression-free survival, which was assessed for differences between treatment arms via one-sided log-rank tests. Results From August 2011 to March 2017, 61 patients were randomly assigned. Forty progression-free survival-related events occurred among 58 evaluable participants. Among all patients, median progression-free survival was 8.0 months (control) versus 12.6 months (experimental; P = .005; hazard ratio [HR], 0.44; 90% CI, 0.26 to 0.76). Similarly, median progression-free survival was 9.3 (control) versus 17.9 (experimental) months among 41 patients with stage III or IV disease undergoing primary treatment ( P = .013; HR, 0.40; 90% CI, 0.20 to 0.80) and 6.0 (control) versus 9.2 months (experimental), respectively, among 17 patients with recurrent disease ( P = .003; HR, 0.14; 90% CI, 0.04 to 0.53). Toxicity was not different between treatment arms, and no unexpected safety signals emerged. Conclusion Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival. These encouraging results deserve further investigation to determine their impact on overall survival in patients with advanced or recurrent uterine serous carcinoma who overexpress HER2/neu.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fader AN, Roque DM, Siegel E, et al. Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. J Clin Oncol. 2018. PMID: 29584549. doi:10.1200/JCO.2017.76.5966

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。